使用孟德尔随机化分析确定治疗炎症性肠病的潜在新目标
Ji-Chang Fan1, Yuan Lu2, Jin-Heng Gan3
1Department of General Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1 Minde Road, Donghu District , Nanchang, 330006, Jiangxi Province, China.
这项研究确定了包括FCGR2A和IL18R1在内的六种关键血蛋白,作为治疗炎症性肠病 (IBD) 和其亚型的有希望的新型药物标,为更有效的治疗提供了希望.
科学领域:
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠病 (IBD) 是一种复杂的自身免疫性疾病,目前的长期治疗疗效不足.
- 对于改善IBD管理的新型治疗点有着至关重要的需求.
研究的目的:
- 使用遗传数据调查血蛋白和IBD之间的因果关系.
- 确定IBD及其亚型的潜在新药点.
主要方法:
- 对全基因组协会研究 (GWAS) 数据进行双样本孟德尔随机化 (MR) 分析.
- 贝叶斯共同本地化以探索共享的遗传变异.
- 对安全性和治疗潜力进行全现象MR和药物向数据库分析.
主要成果:
- 确定了17种蛋白质-IBD对,其中5种蛋白质 (MST1,IL12B,HGFAC,FCGR2A,IL18R1) 与IBD共享遗传位置.
- 特定的蛋白质与性结肠炎 (FCGR2A,IL12B,MST1) 和克罗恩病 (ANGPTL3,IL18R1,MST1) 有关.
- FCGR2A和IL18R1成为潜在的药物点,没有发现全现象MR的不良影响.
结论:
- 六种蛋白质 (FCGR2A,IL18R1,MST1,HGFAC,IL12B和ANGPTL3) 被建议作为IBD的潜在治疗标.
- 这些发现为开发新药物治疗炎症性肠病提供了基础.
- 这项研究强调了基因方法在识别复杂疾病的新药标方面的有用性.
更多相关视频
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
